NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Centre Hospitalier Universitaire, Amiens
Conditions: Covid19, Neurological Manifestations, Brain Damage
Interventions: Magnetic Resonance Spectroscopy (MRS).
Countries: France
Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders. However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Major COVID-19 patient (≥18 years old) * COVID-19 patient presenting at least one the neurological manifestations: anosmia, ageusia, periorbital pain, dizziness, fatigue, moderate headache, moderate memory and behavioral disorders. * Patient who have signed an informed consent form for the study Exclusion Criteria: * Patient under guardianship or curators or under judicial protection * Pregnant and breastfeeding women
- Amiens, France